ALX Oncology Announces Executive and Board Changes
Ticker: ALXO · Form: 8-K · Filed: May 2, 2024 · CIK: 1810182
Sentiment: neutral
Topics: executive-changes, board-of-directors, compensation
Related Tickers: ALXO
TL;DR
ALXO shakes up leadership with new CMO and exec comp updates.
AI Summary
ALX Oncology Holdings Inc. announced on April 28, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Michael J. Yothers was appointed as Chief Medical Officer, and the company also reported on its compensatory arrangements for certain officers.
Why It Matters
Changes in key leadership roles and executive compensation can signal shifts in company strategy and future performance.
Risk Assessment
Risk Level: medium — Changes in executive leadership and compensation can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- Dr. Michael J. Yothers (person) — Appointed Chief Medical Officer
- April 28, 2024 (date) — Date of earliest event reported
FAQ
Who was appointed as the new Chief Medical Officer?
Dr. Michael J. Yothers was appointed as the Chief Medical Officer.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 28, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 323 Allerton Avenue, South San Francisco, California 94080.
What is the Commission File Number for ALX Oncology Holdings Inc.?
The Commission File Number for ALX Oncology Holdings Inc. is 001-39386.
What type of report is this filing?
This filing is a Current Report on Form 8-K.
Filing Stats: 1,052 words · 4 min read · ~4 pages · Grade level 12.8 · Accepted 2024-05-02 16:07:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20240428.htm (8-K) — 47KB
- 0000950170-24-052093.txt ( ) — 158KB
- alxo-20240428.xsd (EX-101.SCH) — 25KB
- alxo-20240428_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date hereof. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in the Company's other filings with the Securities and Exchange Commission, including the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents the Company files with the Securities and Exchange Commission from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: May 2, 2024 By: /s/ Peter Garcia Peter Garcia Chief Financial Officer 2